ATRA
Atara Biotherapeutics, Inc.
$8.34
-16.01%
2026-05-08
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Key Fundamentals
P/E Ratio
3.34
Forward P/E
10.61
EPS (TTM)
$2.57
Revenue Growth (YoY)
-95.1%
Profit Margin
27.1%
Beta
-0.29
Market Cap
$73.2M
Avg Volume (10D)
7.7M
Recent Breakout Signals
No recent breakout signals detected for ATRA.
Recent Price Range (60 Days)
60D High
$12.45
60D Low
$3.92
Avg Volume
1.5M
Latest Close
$8.34
Get breakout alerts for ATRA
Sign up for Breakout Scanner to receive daily notifications when ATRA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Atara Biotherapeutics, Inc. (ATRA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ATRA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ATRA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.